Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix - Related Studies

Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

This study has been completed.

Study NCT00030472. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cervical Cancer

2	Additional conditions recognized in this trial
		Carcinoma, Squamous Cell
		Uterine Cervical Neoplasms

3	More general conditions related to this trial
		Carcinoma
		Genital Diseases, Female
		Genital Neoplasms, Female
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Neoplasms, Squamous Cell
		Urogenital Neoplasms
		Uterine Cervical Diseases
		Uterine Diseases
		Uterine Neoplasms

4	Additional drug interventions recognized in this trial
		Doxorubicin

5	More general drug interventions related to this trial
		Antibiotics, Antineoplastic
		Antineoplastic Agents
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		Gynecologic Oncology Group
		National Cancer Institute (NCI)